Ezekowitz, senior vice president and franchise head, bone, respiratory, immunology and endocrinology, Merck Research Laboratories. Cancer About cachexia syndrome – cancer induced muscle loss occurs in about 50 % of the cancer patients and may lead to loss of protein stores, weakness and fatigue, immobility, loss of independence and lead to the inability to tolerate and respond to cancer treatments. Cancer induced muscle wasting is responsible for at least 20 % of cancer deaths.

Average reported weight loss prior to entry among all subjects was 8.8 %. Subjects were allowed to have standard chemotherapy during the trial. The failure rate during the study was 33 %, lower than the expected 50 % rate observed in other observed in other cancer supportive treatment clinical trials.. The clinical trial was conducted in 159 cancer patients with non-small cell lung cancer, colorectal cancer, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia or breast cancer at 35 sites in the U.S.Let me be clear, I are monitoring progress in which Trust, and when I convinces not it bin move expeditiously, I shall consider to adopt further actions to make sure the patients receive which care it need to and to an employee supported and be good quality environment.